Clinical molecular imaging with positron emission tomography

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1720-1727

  Saleem, Azeem ^a   Charnley, Natalie ^a   Price, Pat ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti cancer drug development; Cyclotron; Fluorodeoxyglucose; Functional imaging; Molecular imaging; Positron emission tomography; Radiotherapy treatment planning; Radiotracer; Response and prognostic evaluation

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; CISPLATIN; COMBRETASTATIN; CYTOTOXIC AGENT; DACARBAZINE; FLUORODEOXYGLUCOSE; FLUOROURACIL; METHIONINE; MISONIDAZOLE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

CANCER; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; MOLECULAR IMAGING; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DIDEOXYNUCLEOSIDES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 33746629469     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.02.021     Document Type: Short Survey

References (50)

1. Anderson H.L., Yap J.T., Miller M.P., Robbins A., Jones T., and Price P.M. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21 15 (2003) 2823-2830
2. Saleem A., Yap J., Osman S., et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 355 9221 (2000) 2125-2131
3. Ell P.J. The contribution of PET/CT to improved patient management. Br J Radiol 79 937 (2006) 32-36
4. Meikle S.R., Matthews J.C., Brock C.S., et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 42 3 (1998) 183-193
5. Lu H., Forbes R.A., and Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277 26 (2002) 23111-23115
6. Khan M.A., Combs C.S., Brunt E.M., et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32 5 (2000) 792-797
7. Shvarts O., Han K.R., Seltzer M., Pantuck A.J., and Belldegrun A.S. Positron emission tomography in urologic oncology. Cancer Control 9 4 (2002) 335-342
8. Wells P., Gunn R.N., Alison M., et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 62 20 (2002) 5698-5702
9. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 11 (1998) 1334-1336
10. Barthel H., Perumal M., Latigo J., et al. The uptake of 3'-deoxy-3'-[(18)F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32 3 (2005) 257-263
11. Lu L., Samuelsson L., Bergstrom M., Sato K., Fasth K.J., and Langstrom B. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 43 12 (2002) 1688-1698
12. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46 6 (2005) 945-952
13. Saleem A., Aboagye E.O., and Price P.M. In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev 41 1 (2000) 21-39
14. Propper D.J., de Bono J., Saleem A., et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 21 2 (2003) 203-210
15. Saleem A., Harte R.J., Matthews J.C., et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 19 5 (2001) 1421-1429
16. Saleem A., Brown G.D., Brady F., et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63 10 (2003) 2409-2415
17. Ginos J.Z., Cooper A.J., Dhawan V., et al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28 12 (1987) 1844-1852
18. Inoue T., Kim E.E., Wallace S., et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 11 4 (1996) 235-245
19. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., and Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 42 suppl 5 (2001) 1S-93S
20. van Tinteren H., Hoekstra O.S., Smit E.F., van den Bergh J.H., Schreurs A.J., Stallaert R.A., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359 9315 (2002) 1388-1393
21. Sharma A., Fidias P., Hayman L.A., Loomis S.L., Taber K.H., and Aquino S.L. Patterns of lymphadenopathy in thoracic malignancies. Radiographics 24 2 (2004) 419-434
22. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11 8 (2005) 2785-2808
23. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 9291 (2001) 1421-1423
24. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 4 (2005) 566-578
25. Mikhaeel N.G., Hutchings M., Fields P.A., O'Doherty M.J., and Timothy A.R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 9 (2005) 1514-1523
26. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 12 (2001) 3058-3065
27. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 24 (2003) 4604-4610
28. Brun E., Kjellen E., Tennvall J., et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 2 (2002) 127-135
29. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23 33 (2005) 8362-8370
30. Cremerius U., Fabry U., Neuerburg J., Zimny M., Bares R., Osieka R., et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin 40 1 (2001) 23-30
31. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 2 (2001) 414-419
32. Weihrauch M.R., Re D., Scheidhauer K., et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98 10 (2001) 2930-2934
33. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 21 (2005) 4652-4661
34. Schuetze S.M., Rubin B.P., Vernon C., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103 2 (2005) 339-348
35. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101 8 (2004) 1776-1785
36. MacManus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 7 (2003) 1285-1292
37. Kunkel M., Forster G.J., Reichert T.E., et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39 2 (2003) 170-177
38. Grigsby P.W., Siegel B.A., Dehdashti F., Rader J., and Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22 11 (2004) 2167-2171
39. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 3 (2000) 317-324
40. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 3 (1999) 593-597
41. Grosu A.L., Piert M., Weber W.A., et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181 8 (2005) 483-499
42. Grosu A.L., Weber W.A., Franz M., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63 2 (2005) 511-519
43. Paxton J.W., Young D., Evans S.M., Kestell P., Robertson I.G., and Cornford E.M. Pharmacokinetics and toxicity of the antitumour agent N-[2- (dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 29 5 (1992) 379-384
44. Baker S.D., Wirth M., Statkevich P., et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5 2 (1999) 309-317
45. Moehler M., Dimitrakopoulou-Strauss A., Gutzler F., Raeth U., Strauss L.G., and Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 83 2 (1998) 245-253
46. Thorwarth D., Eschmann S.M., Paulsen F., and Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 50 10 (2005) 2209-2224
47. Glaser M., Collingridge D.R., Aboagye E.O., et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 58 1 (2003) 55-62
48. Collingridge D.R., Carroll V.A., Glaser M., et al. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62 20 (2002) 5912-5919
49. Blasberg R. PET imaging of gene expression. Eur J Cancer 38 16 (2002) 2137-2146
50. Aboagye E., Saleem A., and Price P. Tumor imaging applications in the testing of new drugs. In: Baguley B., and Kerr D. (Eds). Anticancer drug development (2002), Academic Press, London, UK